The article ‘Can super-antibody drugs be tamed?’ (Nature 440, 855–856; 2006) contained two errors. Steve Anderton researches autoimmune disease, not the use of antibodies to overcome cancer. And he did not state that the CD25 receptor may be a safer target for antibody therapies than CD28; instead, he suggested that CD25 may be of some use as a marker for regulatory T cells, and that other costimulatory molecules, such as CD154, may represent safer targets for immunomodulatory antibodies. Nature apologizes for any confusion.
The online version of the original article can be found at 10.1038/440855a
About this article
Cite this article
Corrections. Nature 441, 141 (2006). https://doi.org/10.1038/441141a